Comparative Study of the Antiarrhythmic Activity of Liposomal Forms of Lappaconitine Hydrobromide and its Complex with Glycyrrhizic Acid Monoammonium Salt in the Aconitine Arrhythmia Model
Results of a comparative study of the antiarrhythmic activity of liposomal forms of lappaconitine hydrobromide (LH) and its complex with the monoammonium salt of glycyrrhizic acid (MASGA) in the aconitine arrhythmia model (pathognomonic for class I antiarrhythmic drugs according to the VaughnWilliam...
Gespeichert in:
| Veröffentlicht in: | Pharmaceutical chemistry journal 2023, Vol.56 (10), p.1327-1332 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1332 |
|---|---|
| container_issue | 10 |
| container_start_page | 1327 |
| container_title | Pharmaceutical chemistry journal |
| container_volume | 56 |
| creator | Uzbekov, V. V. Abdullaev, B. F. Jumayev, I. Z. Oshchepkova, Yu. I. Usmanov, P. B. Salikhov, Sh. I. |
| description | Results of a comparative study of the antiarrhythmic activity of liposomal forms of lappaconitine hydrobromide (LH) and its complex with the monoammonium salt of glycyrrhizic acid (MASGA) in the aconitine arrhythmia model (pathognomonic for class I antiarrhythmic drugs according to the VaughnWilliams classification) and the antiarrhythmic drug Allapinin
®
(lappaconitine hydrobromide) are presented. The liposomal form of LH/MASGA with a LH concentration of 1 ìg/mL is shown to restore effectively the contractile activity of papillary muscle. Moreover, the restored contractile activity persists for a longer time without arrhythmia recurrence than is observed for Allapinin, where arrhythmia recurred after 90 min. It is assumed that the liposomal form of LH/MASGA may become a promising antiarrhythmic drug because of a marked decrease in the toxic effect and a pronounced trend toward a decrease in the time required to restore heart rhythm without arrhythmia recurrence. |
| doi_str_mv | 10.1007/s11094-023-02793-5 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_cross</sourceid><recordid>TN_cdi_gale_infotracmisc_A733884521</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A733884521</galeid><sourcerecordid>A733884521</sourcerecordid><originalsourceid>FETCH-LOGICAL-c358t-ba8d5a3a6a6a0e31924b43af1ef9efc0daaf7fc9dbea6f660a691726ee1d70be3</originalsourceid><addsrcrecordid>eNp9kdGK1DAUhoMoOK6-gFcBr7smzbSdXpbB3RVGvFgF78JpcrKTpUlKklG7z-bDmZ2qIIgcQuDk__6c5CfkNWeXnLHubeKc9duK1aKsrhdV84RseNOJqmeCPyUbxnpe8YZ9eU5epHTPWMFEvSE_9sHNECHbr0hv80kvNBiaj0gHny3EeFzy0VlFB1UkNp-PD3YOKTiY6FWILp1bMM-ggrfZeqQ3i45hjMFZjRS8pjYn-njThN_pN5uP9Hpa1FLc7cPZ22r6IfgAzhWLk6O3MGVq_TrIH9vh9zhQ1Bqnl-SZgSnhq1_7Bfl89e7T_qY6fLx-vx8OlRLNLlcj7HQDAtpSDAXv6-24FWA4mh6NYhrAdEb1ekRoTdsyaHve1S0i1x0bUVyQN6vvHUworTchR1DOJiWHTojdbtvUvKgu_6EqpbF8YPBobOn_BdQroGJIKaKRc7QO4iI5k4-xyjVWWWKV51hlUyCxQqmI_R1GeR9O0Zfn_4_6CSz5qr8</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Comparative Study of the Antiarrhythmic Activity of Liposomal Forms of Lappaconitine Hydrobromide and its Complex with Glycyrrhizic Acid Monoammonium Salt in the Aconitine Arrhythmia Model</title><source>SpringerLink Journals - AutoHoldings</source><creator>Uzbekov, V. V. ; Abdullaev, B. F. ; Jumayev, I. Z. ; Oshchepkova, Yu. I. ; Usmanov, P. B. ; Salikhov, Sh. I.</creator><creatorcontrib>Uzbekov, V. V. ; Abdullaev, B. F. ; Jumayev, I. Z. ; Oshchepkova, Yu. I. ; Usmanov, P. B. ; Salikhov, Sh. I.</creatorcontrib><description>Results of a comparative study of the antiarrhythmic activity of liposomal forms of lappaconitine hydrobromide (LH) and its complex with the monoammonium salt of glycyrrhizic acid (MASGA) in the aconitine arrhythmia model (pathognomonic for class I antiarrhythmic drugs according to the VaughnWilliams classification) and the antiarrhythmic drug Allapinin
®
(lappaconitine hydrobromide) are presented. The liposomal form of LH/MASGA with a LH concentration of 1 ìg/mL is shown to restore effectively the contractile activity of papillary muscle. Moreover, the restored contractile activity persists for a longer time without arrhythmia recurrence than is observed for Allapinin, where arrhythmia recurred after 90 min. It is assumed that the liposomal form of LH/MASGA may become a promising antiarrhythmic drug because of a marked decrease in the toxic effect and a pronounced trend toward a decrease in the time required to restore heart rhythm without arrhythmia recurrence.</description><identifier>ISSN: 0091-150X</identifier><identifier>EISSN: 1573-9031</identifier><identifier>DOI: 10.1007/s11094-023-02793-5</identifier><language>eng</language><publisher>New York: Springer US</publisher><subject>Anti-arrhythmia drugs ; Arrhythmia ; Comparative analysis ; Heart beat ; Medicine ; Organic Chemistry ; Pharmacology/Toxicology ; Pharmacy</subject><ispartof>Pharmaceutical chemistry journal, 2023, Vol.56 (10), p.1327-1332</ispartof><rights>Springer Science+Business Media, LLC, part of Springer Nature 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.</rights><rights>COPYRIGHT 2023 Springer</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c358t-ba8d5a3a6a6a0e31924b43af1ef9efc0daaf7fc9dbea6f660a691726ee1d70be3</citedby><cites>FETCH-LOGICAL-c358t-ba8d5a3a6a6a0e31924b43af1ef9efc0daaf7fc9dbea6f660a691726ee1d70be3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s11094-023-02793-5$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s11094-023-02793-5$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,777,781,27905,27906,41469,42538,51300</link.rule.ids></links><search><creatorcontrib>Uzbekov, V. V.</creatorcontrib><creatorcontrib>Abdullaev, B. F.</creatorcontrib><creatorcontrib>Jumayev, I. Z.</creatorcontrib><creatorcontrib>Oshchepkova, Yu. I.</creatorcontrib><creatorcontrib>Usmanov, P. B.</creatorcontrib><creatorcontrib>Salikhov, Sh. I.</creatorcontrib><title>Comparative Study of the Antiarrhythmic Activity of Liposomal Forms of Lappaconitine Hydrobromide and its Complex with Glycyrrhizic Acid Monoammonium Salt in the Aconitine Arrhythmia Model</title><title>Pharmaceutical chemistry journal</title><addtitle>Pharm Chem J</addtitle><description>Results of a comparative study of the antiarrhythmic activity of liposomal forms of lappaconitine hydrobromide (LH) and its complex with the monoammonium salt of glycyrrhizic acid (MASGA) in the aconitine arrhythmia model (pathognomonic for class I antiarrhythmic drugs according to the VaughnWilliams classification) and the antiarrhythmic drug Allapinin
®
(lappaconitine hydrobromide) are presented. The liposomal form of LH/MASGA with a LH concentration of 1 ìg/mL is shown to restore effectively the contractile activity of papillary muscle. Moreover, the restored contractile activity persists for a longer time without arrhythmia recurrence than is observed for Allapinin, where arrhythmia recurred after 90 min. It is assumed that the liposomal form of LH/MASGA may become a promising antiarrhythmic drug because of a marked decrease in the toxic effect and a pronounced trend toward a decrease in the time required to restore heart rhythm without arrhythmia recurrence.</description><subject>Anti-arrhythmia drugs</subject><subject>Arrhythmia</subject><subject>Comparative analysis</subject><subject>Heart beat</subject><subject>Medicine</subject><subject>Organic Chemistry</subject><subject>Pharmacology/Toxicology</subject><subject>Pharmacy</subject><issn>0091-150X</issn><issn>1573-9031</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><recordid>eNp9kdGK1DAUhoMoOK6-gFcBr7smzbSdXpbB3RVGvFgF78JpcrKTpUlKklG7z-bDmZ2qIIgcQuDk__6c5CfkNWeXnLHubeKc9duK1aKsrhdV84RseNOJqmeCPyUbxnpe8YZ9eU5epHTPWMFEvSE_9sHNECHbr0hv80kvNBiaj0gHny3EeFzy0VlFB1UkNp-PD3YOKTiY6FWILp1bMM-ggrfZeqQ3i45hjMFZjRS8pjYn-njThN_pN5uP9Hpa1FLc7cPZ22r6IfgAzhWLk6O3MGVq_TrIH9vh9zhQ1Bqnl-SZgSnhq1_7Bfl89e7T_qY6fLx-vx8OlRLNLlcj7HQDAtpSDAXv6-24FWA4mh6NYhrAdEb1ekRoTdsyaHve1S0i1x0bUVyQN6vvHUworTchR1DOJiWHTojdbtvUvKgu_6EqpbF8YPBobOn_BdQroGJIKaKRc7QO4iI5k4-xyjVWWWKV51hlUyCxQqmI_R1GeR9O0Zfn_4_6CSz5qr8</recordid><startdate>2023</startdate><enddate>2023</enddate><creator>Uzbekov, V. V.</creator><creator>Abdullaev, B. F.</creator><creator>Jumayev, I. Z.</creator><creator>Oshchepkova, Yu. I.</creator><creator>Usmanov, P. B.</creator><creator>Salikhov, Sh. I.</creator><general>Springer US</general><general>Springer</general><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>2023</creationdate><title>Comparative Study of the Antiarrhythmic Activity of Liposomal Forms of Lappaconitine Hydrobromide and its Complex with Glycyrrhizic Acid Monoammonium Salt in the Aconitine Arrhythmia Model</title><author>Uzbekov, V. V. ; Abdullaev, B. F. ; Jumayev, I. Z. ; Oshchepkova, Yu. I. ; Usmanov, P. B. ; Salikhov, Sh. I.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c358t-ba8d5a3a6a6a0e31924b43af1ef9efc0daaf7fc9dbea6f660a691726ee1d70be3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Anti-arrhythmia drugs</topic><topic>Arrhythmia</topic><topic>Comparative analysis</topic><topic>Heart beat</topic><topic>Medicine</topic><topic>Organic Chemistry</topic><topic>Pharmacology/Toxicology</topic><topic>Pharmacy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Uzbekov, V. V.</creatorcontrib><creatorcontrib>Abdullaev, B. F.</creatorcontrib><creatorcontrib>Jumayev, I. Z.</creatorcontrib><creatorcontrib>Oshchepkova, Yu. I.</creatorcontrib><creatorcontrib>Usmanov, P. B.</creatorcontrib><creatorcontrib>Salikhov, Sh. I.</creatorcontrib><collection>CrossRef</collection><jtitle>Pharmaceutical chemistry journal</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Uzbekov, V. V.</au><au>Abdullaev, B. F.</au><au>Jumayev, I. Z.</au><au>Oshchepkova, Yu. I.</au><au>Usmanov, P. B.</au><au>Salikhov, Sh. I.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Comparative Study of the Antiarrhythmic Activity of Liposomal Forms of Lappaconitine Hydrobromide and its Complex with Glycyrrhizic Acid Monoammonium Salt in the Aconitine Arrhythmia Model</atitle><jtitle>Pharmaceutical chemistry journal</jtitle><stitle>Pharm Chem J</stitle><date>2023</date><risdate>2023</risdate><volume>56</volume><issue>10</issue><spage>1327</spage><epage>1332</epage><pages>1327-1332</pages><issn>0091-150X</issn><eissn>1573-9031</eissn><abstract>Results of a comparative study of the antiarrhythmic activity of liposomal forms of lappaconitine hydrobromide (LH) and its complex with the monoammonium salt of glycyrrhizic acid (MASGA) in the aconitine arrhythmia model (pathognomonic for class I antiarrhythmic drugs according to the VaughnWilliams classification) and the antiarrhythmic drug Allapinin
®
(lappaconitine hydrobromide) are presented. The liposomal form of LH/MASGA with a LH concentration of 1 ìg/mL is shown to restore effectively the contractile activity of papillary muscle. Moreover, the restored contractile activity persists for a longer time without arrhythmia recurrence than is observed for Allapinin, where arrhythmia recurred after 90 min. It is assumed that the liposomal form of LH/MASGA may become a promising antiarrhythmic drug because of a marked decrease in the toxic effect and a pronounced trend toward a decrease in the time required to restore heart rhythm without arrhythmia recurrence.</abstract><cop>New York</cop><pub>Springer US</pub><doi>10.1007/s11094-023-02793-5</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0091-150X |
| ispartof | Pharmaceutical chemistry journal, 2023, Vol.56 (10), p.1327-1332 |
| issn | 0091-150X 1573-9031 |
| language | eng |
| recordid | cdi_gale_infotracmisc_A733884521 |
| source | SpringerLink Journals - AutoHoldings |
| subjects | Anti-arrhythmia drugs Arrhythmia Comparative analysis Heart beat Medicine Organic Chemistry Pharmacology/Toxicology Pharmacy |
| title | Comparative Study of the Antiarrhythmic Activity of Liposomal Forms of Lappaconitine Hydrobromide and its Complex with Glycyrrhizic Acid Monoammonium Salt in the Aconitine Arrhythmia Model |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-19T01%3A13%3A35IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Comparative%20Study%20of%20the%20Antiarrhythmic%20Activity%20of%20Liposomal%20Forms%20of%20Lappaconitine%20Hydrobromide%20and%20its%20Complex%20with%20Glycyrrhizic%20Acid%20Monoammonium%20Salt%20in%20the%20Aconitine%20Arrhythmia%20Model&rft.jtitle=Pharmaceutical%20chemistry%20journal&rft.au=Uzbekov,%20V.%20V.&rft.date=2023&rft.volume=56&rft.issue=10&rft.spage=1327&rft.epage=1332&rft.pages=1327-1332&rft.issn=0091-150X&rft.eissn=1573-9031&rft_id=info:doi/10.1007/s11094-023-02793-5&rft_dat=%3Cgale_cross%3EA733884521%3C/gale_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rft_galeid=A733884521&rfr_iscdi=true |